Intercept Pharmaceuticals, a U.S. biotechnology company focused on advanced treatments for liver disease, is exploring a potential sale after receiving interest from other companies, according to people familiar with the matter.
Intercept has been working with investment bankers to explore the prospect of a sale, the people said this week, cautioning that there was no certainty on whether the company would decide to proceed with any transaction.
The sources asked not to be identified because the sale process is confidential. Intercept declined to comment.
Shares of Intercept Pharmaceuticals were up more than 30 percent in afternoon trading on Friday.
— CNBC contributed to this report